Explore the list of already confirmed speakers for MSS2026, showcasing innovative approaches and cutting-edge research in their respective fields. This list is set to grow as additional speakers are confirmed. We invite you to register and submit your abstract for presentation to join this esteemed group of prominent speakers. Be part of the conversation and contribute to the future of science and technology.
Non-viral, polymeric nanoparticle gene therapy for ocular disorders
Niren Shah and Andrew Knudten (Cove Therapeutics, USA, CA)
How rapid in-process analytics unlocks hidden potential in mRNA process development
Rok Sekirnik (Sartorius BIA Separations, Slovenia)
tLNP as a novel gene therapy vector to deliver DNA – are we there yet?
Jacek Lubelski (NanoCell, Netherlands)
Away from Cohn, away from EtOH, the next generation plasma fractionation process
Aleš Štrancar (Sartorius BIA Separations, Slovenia)
Commercial-ready plasmid manufacturing: scaling late-stage cell & gene therapy with regulatory confidence
Christy Franco (VGXI, USA, TX)
Monoliths in plasma fractionation – new trends and perspectives
Djuro Josić (Juraj Dobrila University of Pula, Croatia)
A comprehensive manufacturing and characterization approach to passive or active targeted LNP-based biopharmaceuticals
Tristan Kovačič (Sartorius BIA Separations, Slovenia)
Monolith-based immobilized enzyme reactors: enabling technologies for diverse and evolving landscapes
Manuela Bartolini (Alma Mater Studiorum University of Bologna, Italy)
Advancing biomanufacturing education: adapting workforce development for the next generation of biologics
Gary Gilleskie (Biomanufacturing Training and Education Center (BTEC), USA, NC)
The RNA revolution: from novel vaccines to therapeutic genome editing
Dan Peer (Laboratory of Precision Nanomedicine, Tel Aviv University, Israel)
Fighting CTNNB1 syndrome with AAV gene therapy: a mission to change the world
Špela Miroševič (CTNNB1 Foundation, Slovenia)
Chromatographic LNP purification for enhanced purity and activity in CRISPR, CAR-T, and vaccine manufacturing
Mojca Tajnik Sbaizero (Sartorius BIA Separations, Slovenia)
Commercial scale evaluation of a mixed mode CIMmultus® monolithic column in the production of human immunoglobulin products
Andre Germishuizen (National Bioproducts Institute (NBI), South Africa)
delNS – an interferon inducing viral vector to tackle head & neck cancer
Thomas Muster (BlueSky Immunotherapies, Austria)
Affinity and mixed-mode convective adsorbents for the purification and enrichment of vectors for cell and gene therapies
Stefano Menegatti (North Carolina State University, USA, NC)
The wonderful world of nucleic acid diversity through the eyes of a monolithic chromatography column
Urh Černigoj (Sartorius BIA Separations, Slovenia)
Monitoring mRNA vaccine process development using PATfix HPLC
Yijun Zhou (National Institutes of Health (NIH),USA, MD)